Table 3– Percentage of failures and relapses that are predicted to have persistent or acquired drug resistance after standardised initial and retreatment regimens
CountryInitial regimenAmong failures of retreatmentAmong relapses after retreatment
Pan-sensitive %ResistancePan-sensitive %Resistance
Persistent#AcquiredPersistent#Acquired
Dominican Republic2HRZE/6HE09464914
2HRZE/4HR09912971
Peru2HRZE/6HE193711845
2HRZE/4HR09916931
Vietnam2HRZE/6HE1772297813
2HRZE/4HR09736922
UR Tanzania2HRZE/6HE3831435587
2HRZE/4HR196320772
Nicaragua2HRZE/6HE37622325810
2HRZE/4HR195419783
Gambia2HRZE/6HE3861041545
2HRZE/4HR196323742
Kenya2HRZE/6HE102861513612
2HRZE/4HR289835605
  • Data are presented as % and rounded to whole numbers. 2HRZE: isoniazid, rifampin, pyrazinamide and ethambutol for 2 months; 6HE: isoniazid plus ethambutol for 6 months; 4HR: isoniazid plus rifampin for 4 months. #: persistent drug resistance is defined as resistance that exists at the start and remains throughout treatment; : acquired drug resistance is defined as resistance that is amplified or occurs de novo during a course of treatment.